FR06C0014I2 - - Google Patents

Info

Publication number
FR06C0014I2
FR06C0014I2 FR06C0014C FR06C0014C FR06C0014I2 FR 06C0014 I2 FR06C0014 I2 FR 06C0014I2 FR 06C0014 C FR06C0014 C FR 06C0014C FR 06C0014 C FR06C0014 C FR 06C0014C FR 06C0014 I2 FR06C0014 I2 FR 06C0014I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR06C0014C
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of FR06C0014I1 publication Critical patent/FR06C0014I1/fr
Application granted granted Critical
Publication of FR06C0014I2 publication Critical patent/FR06C0014I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR06C0014C 1995-03-27 2006-04-04 Active FR06C0014I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
FR06C0014I1 FR06C0014I1 (fr) 2006-11-17
FR06C0014I2 true FR06C0014I2 (fr) 2006-12-29

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0014C Active FR06C0014I2 (fr) 1995-03-27 2006-04-04

Country Status (25)

Country Link
US (1) US5900431A (fr)
EP (1) EP0817626B1 (fr)
JP (1) JP3260378B2 (fr)
KR (1) KR100286920B1 (fr)
CN (1) CN1072485C (fr)
AP (1) AP646A (fr)
AT (1) ATE172641T1 (fr)
AU (1) AU706161B2 (fr)
CA (1) CA2216623C (fr)
CZ (1) CZ286821B6 (fr)
DE (1) DE69600879T2 (fr)
DK (1) DK0817626T3 (fr)
EA (1) EA000150B1 (fr)
ES (1) ES2128846T3 (fr)
FR (1) FR06C0014I2 (fr)
HU (1) HU224028B1 (fr)
IS (1) IS2048B (fr)
NO (1) NO315968B1 (fr)
NZ (1) NZ304906A (fr)
OA (1) OA10515A (fr)
PL (1) PL183378B1 (fr)
SK (1) SK283883B6 (fr)
TR (1) TR199701048T1 (fr)
UA (1) UA41446C2 (fr)
WO (1) WO1996030010A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900431A (en) * 1995-03-27 1999-05-04 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (fr) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Composition orale contenant un dérivé de fumagillol
DE60034770T2 (de) 1999-02-26 2008-04-30 Sanofi-Aventis Stabile fumagillin-formulierung
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
WO2009073445A2 (fr) * 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Conjugués d'analogues de fumagilline biocompatibles et biodégradables
AU2009270799B2 (en) * 2008-07-18 2016-05-19 Zafgen, Inc. Methods of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2010065883A2 (fr) 2008-12-04 2010-06-10 Zafgen Corporation Procédés de traitement d'un sujet présentant un état de surpoids ou d'obésité
WO2013055385A2 (fr) 2011-10-03 2013-04-18 Zafgen Corporation Méthodes de traitement de troubles liés à l'âge
WO2011044506A2 (fr) 2009-10-09 2011-04-14 Zafgen Corporation Composés sulfonés et leurs procédés de fabrication et d'utilisation
WO2011085198A1 (fr) 2010-01-08 2011-07-14 Zafgen Corporation Inhibiteur de metap-2 pour utilisation dans le traitement d'une hypertrophie bénigne de la prostate (bph)
EP2521719B1 (fr) 2010-01-08 2015-07-29 Zafgen, Inc. Composés de type fumagillol, et procédés correspondants de fabrication et d'utilisation
WO2011127304A2 (fr) 2010-04-07 2011-10-13 Zafgen Corporation Méthodes de traitement d'un sujet en surpoids
AU2011281037B2 (en) 2010-07-22 2014-11-27 Zafgen, Inc. Tricyclic compounds and methods of making and using same
WO2012064838A1 (fr) 2010-11-09 2012-05-18 Zafgen Corporation Solides cristallins d'inhibiteur de metap-2 et leurs procédés de production et d'utilisation
CA2819251A1 (fr) 2010-11-29 2012-06-07 Zafgen Corporation Traitement de l'obesite a l'aide d'une administration non quotidienne de 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
CA2825408A1 (fr) 2011-01-26 2012-08-02 Zafgen, Inc. Composes de tetrazole et procedes de preparation et d'utilisation de ceux-ci
MX342257B (es) 2011-03-08 2016-09-21 Zafgen Inc Derivados y análogos de oxaspiro [2.5] octano.
WO2012154676A1 (fr) 2011-05-06 2012-11-15 Zafgen Corporation Composés tricycliques partiellement saturés et leurs procédés de fabrication et d'utilisation
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
CA2835195A1 (fr) 2011-05-06 2012-11-15 Zafgen, Inc. Composes de sulfonamide tricycliques et leurs procedes de fabrication et d'utilisation
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
KR20140112566A (ko) 2012-01-18 2014-09-23 자프겐 인크. 삼환식 설폰 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
AU2013259760A1 (en) 2012-05-07 2014-11-20 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol and methods of making and using same
AU2013259617A1 (en) 2012-05-08 2014-11-27 Zafgen, Inc. Treating hypothalamic obesity with MetAP2 inhibitors
AU2013259620B2 (en) 2012-05-09 2017-05-18 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
EP2925737B1 (fr) 2012-11-05 2017-06-14 Zafgen, Inc. Composés tricycliques à utiliser dans le traitement et/ou la lutte contre l'obésité
AU2013337282A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds and methods of making and using same
CA2890343A1 (fr) 2012-11-05 2014-05-08 Zafgen, Inc. Composes tricycliques utiles pour le traitement de troubles hepatiques
CN105228610A (zh) 2013-03-14 2016-01-06 扎夫根股份有限公司 治疗肾疾病和其它病症的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
WO1992002240A2 (fr) * 1990-07-27 1992-02-20 Repligen Corporation Compositions et procedes nouveaux pour le traitement des maladies angiogeniques
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
US5900431A (en) * 1995-03-27 1999-05-04 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (fr) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Composition orale contenant un dérivé de fumagillol
CA2210600A1 (fr) * 1996-07-17 1998-01-17 Takashi Houkan Inhibiteur des metastases tumorales ou de la recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
DK0817626T3 (da) 1999-07-12
EA199700267A1 (ru) 1998-04-30
JP3260378B2 (ja) 2002-02-25
SK130797A3 (en) 1998-03-04
CZ304997A3 (en) 1997-12-17
IS2048B (is) 2005-09-15
AP9701092A0 (en) 1997-10-31
AU706161B2 (en) 1999-06-10
CA2216623C (fr) 2005-05-31
HUP9801220A2 (hu) 1999-09-28
SK283883B6 (sk) 2004-04-06
NO974466L (no) 1997-09-26
AP646A (en) 1998-04-27
KR100286920B1 (ko) 2001-04-16
CZ286821B6 (en) 2000-07-12
PL322470A1 (en) 1998-02-02
PL183378B1 (pl) 2002-06-28
IS4557A (is) 1997-09-11
AU5278696A (en) 1996-10-16
EP0817626A2 (fr) 1998-01-14
WO1996030010A3 (fr) 1996-11-28
KR19980703271A (ko) 1998-10-15
MX9707150A (es) 1998-07-31
OA10515A (fr) 2002-04-24
EP0817626B1 (fr) 1998-10-28
UA41446C2 (uk) 2001-09-17
FR06C0014I1 (fr) 2006-11-17
DE69600879D1 (de) 1998-12-03
HUP9801220A3 (en) 2001-10-29
DE69600879T2 (de) 1999-06-02
US5900431A (en) 1999-05-04
ES2128846T3 (es) 1999-05-16
JPH11506421A (ja) 1999-06-08
CA2216623A1 (fr) 1996-10-03
ATE172641T1 (de) 1998-11-15
EA000150B1 (ru) 1998-10-29
CN1072485C (zh) 2001-10-10
NO974466D0 (no) 1997-09-26
TR199701048T1 (xx) 1998-01-21
HU224028B1 (hu) 2005-05-30
WO1996030010A2 (fr) 1996-10-03
CN1179715A (zh) 1998-04-22
NZ304906A (en) 1999-06-29
NO315968B1 (no) 2003-11-24

Similar Documents

Publication Publication Date Title
DE69638352D1 (fr)
DE69637714D1 (fr)
FR06C0014I2 (fr)
BR122012014331A2 (fr)
BRPI9612258B1 (fr)
BRPI9612138B1 (fr)
DK143195A (fr)
EP0774685A3 (fr)
EP0762592A3 (fr)
CH0741373H1 (fr)
DK0727898T3 (fr)
IN184639B (fr)
BR7501503U (fr)
AU1627395A (fr)
DK126096A (fr)
BR7502120U (fr)
IN184628B (fr)
IN184752B (fr)
IN185251B (fr)
CN3037560S (fr)
CN3035871S (fr)
CN3037606S (fr)
EP0871420A4 (fr)
CN3035869S (fr)
CN3037433S (fr)